Reports suggested that the activation of GSK-3β, which phosphorylates β-catenin, is regulated by the PI3K/Akt pathway and in glioma, LY294002-induced inhibition of PI3K decreased cell proliferation and cell invasiveness through the downregulation of members of the Wnt/β-catenin pathway, including GSK-3β and β-catenin [107,108]. This evidence concerns the gene GSK3B and central nervous system cancer.